Lavina Talukdar - Mar 4, 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Director
Signature
/s/ Quan Vu, Attorney-in-fact
Stock symbol
MNPR
Transactions as of
Mar 4, 2025
Transactions value $
$0
Form type
4
Date filed
3/7/2025, 07:51 PM
Previous filing
Mar 6, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Award $0 +5.68K $0.00 5.68K Mar 4, 2025 Common Stock 5.68K $31.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025